Zimmer Biomet secures $2.75 billion credit, shares under Wall Street scrutiny

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 13:25.

Zimmer Biomet Holdings, Inc. (US98956P1021) has strengthened its financing lines with fresh revolving credit capacity. The New York Stock Exchange-listed medical technology group now has $2.75 billion of unsecured borrowing available after new agreements signed on June 26, 2026, according to a recent company statement.

New JPMorgan-led credit facilities

Zimmer Biomet has entered into two new revolving credit agreements with JPMorgan Chase Bank, N.A. as administrative agent, replacing earlier lines from June 2025 that were terminated with no outstanding balance reported at the time. An Investing.com summary of the transaction notes that the combined unsecured capacity from the new facilities stands at $2.75 billion.

The first facility is a five-year revolving credit line of $1.5 billion maturing on June 26, 2031, with two optional one-year extensions that Zimmer Biomet can request subject to lender consent. The agreement allows for an uncommitted incremental feature of up to $750 million, giving the company scope to lift the line if conditions permit, while maintaining a floating interest rate based on adjusted Term SOFR or an alternate base rate plus a margin linked to its senior unsecured long-term debt rating.

Shorter 364-day facility and covenant framework

Alongside the five-year line, Zimmer Biomet has put in place a 364-day revolving credit facility of $1.25 billion maturing on June 25, 2027, also administered by JPMorgan Chase Bank. Both facilities share a covenant that requires the company to keep consolidated indebtedness to consolidated EBITDA at or below 4.5 to 1.0, with room for this ratio to rise to 5.0 to 1.0 in connection with a qualified material acquisition, reflecting an allowance for larger deals. The same Investing.com report highlights that proceeds from both facilities are earmarked for general corporate purposes.

The company paid roughly $0.4 million in fees related to the termination of the prior five-year revolving agreement, funded from cash on hand. No principal was outstanding on either of the terminated facilities, which simplifies the migration to the new structure without immediate repayment pressure and keeps the focus on future liquidity use.

Aggregated analyst targets and ratings picture

On the analyst side, Zimmer Biomet shares carry a broad range of published 12-month price targets, reflecting differing views on the mid-term earnings path for the orthopedic device maker. One recent aggregation of Wall Street forecasts as of June 30, 2026 cites a median target of $172.86 per share for ZBH, with high estimates reaching $266.71 and low scenarios at $65.84, based on 76 individual price targets in the dataset.

The same compilation presents a distribution of analyst recommendations over the past three months, indicating roughly 19 percent Buy, 18 percent Hold and 63 percent Sell ratings, which translates into a cautious consensus label on the stock in that source’s methodology. The Bitget analyst overview also mentions projected next-quarter earnings per share of just over $2 and revenue expectations around $2.14 billion, figures that frame the near-term fundamental narrative behind the published price targets.

Orthopedic implants at the core

Zimmer Biomet’s core business centers on musculoskeletal health, with a broad portfolio spanning knee, hip and other joint reconstruction systems for surgical use. A flagship product line in the knee segment is the Persona Knee System, which combines modular components, multiple bearing options and patient-specific sizing to give surgeons flexibility in primary knee replacement procedures and has become a bestseller within the company’s reconstruction offering.

Where the stock trades today

Zimmer Biomet shares (US98956P1021) trade on 2026-06-30, 13:25 on the New York Stock Exchange at around $93.10 per share, based on the most recently available closing and intraday indications in US dollars.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. All data and assessments are based on sources deemed reliable at the time of publication but may change without notice.